首页 > 最新文献

Reviews on recent clinical trials最新文献

英文 中文
Non-alcoholic Wernicke Encephalopathy in a Young Patient with Adenocarcinoma of the Colon: A Case Report and Review of the Literature. 结肠腺癌年轻患者的非酒精性韦尼克脑病:病例报告和文献综述。
IF 1.4 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-10-30 DOI: 10.2174/0115748871320420241016060051
Afroditi Ziogou, Andreas Lymperis, Nikolaos Skouteris, Georgios Papageorgiou, Nikolaos Charalampakis

Introduction: Wernicke Encephalopathy (W.E.) is an acute neurological disorder induced by thiamine deficiency. Alcohol abuse is considered to be the leading cause of the disease; however, numerous other conditions, such as malnutrition or cancer, have been identified as potential risk factors.

Case presentation: Clinical manifestations include a typical triad of mental status alteration, nystagmus, and ataxia and are attributed to damage in brain regions of high thiamine demand. The diagnosis is mainly clinical and further supported by the immediate response of neurological signs to parenteral thiamine administration. Among paraclinical examinations, brain MRI is considered substantial for diagnosis and is supported by the determination of thiamine blood levels.

Conclusion: Non-alcoholic W.E. is trickier to diagnose due to its atypical clinical course and risk factors. We herein describe a case of non-alcoholic W.E. in a woman with colon cancer who gradually developed the classic symptoms of thiamine deficiency.

导言韦尼克脑病(Wernicke Encephalopathy,W.E.)是一种由硫胺素缺乏引起的急性神经系统疾病。酗酒被认为是导致该病的主要原因,然而,营养不良或癌症等许多其他疾病也被认为是潜在的危险因素:临床表现包括典型的精神状态改变、眼球震颤和共济失调三联征,归因于对硫胺素需求较高的脑区受损。诊断主要依靠临床表现,而神经系统体征对肠道外注射硫胺素的即时反应则进一步证实了这一点。在辅助临床检查中,脑核磁共振成像被认为是诊断的重要依据,并通过测定血液中的硫胺素水平来支持诊断:结论:非酒精性 W.E. 由于其不典型的临床过程和风险因素,诊断起来较为棘手。我们在此描述了一例患有结肠癌的女性非酒精性 W.E.患者,她逐渐出现了典型的硫胺素缺乏症状。
{"title":"Non-alcoholic Wernicke Encephalopathy in a Young Patient with Adenocarcinoma of the Colon: A Case Report and Review of the Literature.","authors":"Afroditi Ziogou, Andreas Lymperis, Nikolaos Skouteris, Georgios Papageorgiou, Nikolaos Charalampakis","doi":"10.2174/0115748871320420241016060051","DOIUrl":"10.2174/0115748871320420241016060051","url":null,"abstract":"<p><strong>Introduction: </strong>Wernicke Encephalopathy (W.E.) is an acute neurological disorder induced by thiamine deficiency. Alcohol abuse is considered to be the leading cause of the disease; however, numerous other conditions, such as malnutrition or cancer, have been identified as potential risk factors.</p><p><strong>Case presentation: </strong>Clinical manifestations include a typical triad of mental status alteration, nystagmus, and ataxia and are attributed to damage in brain regions of high thiamine demand. The diagnosis is mainly clinical and further supported by the immediate response of neurological signs to parenteral thiamine administration. Among paraclinical examinations, brain MRI is considered substantial for diagnosis and is supported by the determination of thiamine blood levels.</p><p><strong>Conclusion: </strong>Non-alcoholic W.E. is trickier to diagnose due to its atypical clinical course and risk factors. We herein describe a case of non-alcoholic W.E. in a woman with colon cancer who gradually developed the classic symptoms of thiamine deficiency.</p>","PeriodicalId":21174,"journal":{"name":"Reviews on recent clinical trials","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142558649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ongoing Clinical Trials for Polycystic Ovarian Syndrome (PCOS) Afflicted Infertility in Women: A Narrative Review. 针对多囊卵巢综合征(PCOS)所致女性不孕症的现行临床试验:叙述性综述。
IF 1.4 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-10-17 DOI: 10.2174/0115748871325070241008101355
Ratnakar Shukla, Muskan Chadha, Anisha Adya, Aastha Yadav, Nidhi Singh, Ranjeet Singh Chauhan, Afza Ahmad, Rohit Kumar Tiwari

Polycystic Ovary Syndrome (PCOS) is a highly prevalent endocrine disorder that affects women of reproductive age. PCOS is further correlated with infertility, menstrual dysfunction, and hyperandrogenism. Despite the advanced understanding of reproductive biology, the exact causes of PCOS remain ambiguous. Nevertheless, several factors are believed to contribute to the development of PCOS, including insulin resistance, hyperinsulinemia, obesity, and genetic predispositions. The diagnosis of PCOS is complicated by its phenotypic heterogeneity, which manifests differently in different individuals. Presently, the therapeutic management of PCOS-afflicted infertility depends upon proper pharmaceutical-based therapies aimed at treating underlying symptoms, such as the use of clomiphene citrate, metformin, ovulation-inducing agents, anti-androgens, exogenous gonadotropin administration, laparoscopic ovarian drilling, and in vitro fertilization. The present review focuses on narrating present therapeutic interventions along with lifestyle modifications in PCOS. Furthermore, it focuses on the ongoing clinical trials of various chemotherapeutics to counter PCOS-induced infertility among women.

多囊卵巢综合症(PCOS)是一种影响育龄妇女的高发内分泌疾病。多囊卵巢综合症还与不孕、月经功能障碍和高雄激素有关。尽管人们对生殖生物学有了更深入的了解,但多囊卵巢综合症的确切病因仍不明确。不过,有几种因素被认为会导致多囊卵巢综合症的发生,包括胰岛素抵抗、高胰岛素血症、肥胖和遗传倾向。多囊卵巢综合征的表型具有异质性,在不同的个体身上表现出不同的症状,这使得多囊卵巢综合征的诊断变得更加复杂。目前,治疗多囊卵巢综合征引起的不孕症主要依靠适当的药物疗法,以治疗潜在症状,如使用枸橼酸氯米芬、二甲双胍、促排卵药、抗雄激素、外源性促性腺激素、腹腔镜卵巢钻孔术和体外受精。本综述重点阐述了目前对多囊卵巢综合症的治疗干预措施以及生活方式的改变。此外,它还重点介绍了目前正在进行的各种化疗药物的临床试验,以应对多囊卵巢综合症诱发的女性不孕症。
{"title":"Ongoing Clinical Trials for Polycystic Ovarian Syndrome (PCOS) Afflicted Infertility in Women: A Narrative Review.","authors":"Ratnakar Shukla, Muskan Chadha, Anisha Adya, Aastha Yadav, Nidhi Singh, Ranjeet Singh Chauhan, Afza Ahmad, Rohit Kumar Tiwari","doi":"10.2174/0115748871325070241008101355","DOIUrl":"https://doi.org/10.2174/0115748871325070241008101355","url":null,"abstract":"<p><p>Polycystic Ovary Syndrome (PCOS) is a highly prevalent endocrine disorder that affects women of reproductive age. PCOS is further correlated with infertility, menstrual dysfunction, and hyperandrogenism. Despite the advanced understanding of reproductive biology, the exact causes of PCOS remain ambiguous. Nevertheless, several factors are believed to contribute to the development of PCOS, including insulin resistance, hyperinsulinemia, obesity, and genetic predispositions. The diagnosis of PCOS is complicated by its phenotypic heterogeneity, which manifests differently in different individuals. Presently, the therapeutic management of PCOS-afflicted infertility depends upon proper pharmaceutical-based therapies aimed at treating underlying symptoms, such as the use of clomiphene citrate, metformin, ovulation-inducing agents, anti-androgens, exogenous gonadotropin administration, laparoscopic ovarian drilling, and in vitro fertilization. The present review focuses on narrating present therapeutic interventions along with lifestyle modifications in PCOS. Furthermore, it focuses on the ongoing clinical trials of various chemotherapeutics to counter PCOS-induced infertility among women.</p>","PeriodicalId":21174,"journal":{"name":"Reviews on recent clinical trials","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2024-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142473536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Etiology, Recent Advances, and Clinical Trials Data for the Treatment of Angioedema: A Review. 治疗血管性水肿的病因、最新进展和临床试验数据:综述。
IF 1.4 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-10-11 DOI: 10.2174/0115748871307432240930051749
Mukul Nishad, Sushma Verma, Ramish Maqsood, Rashmi Saxena Pal

Angioedema is a health issue that affects parts of the body like the upper pulmonary and gastric pathways and is identified by abrupt, nonpitting enlargement of the skin, mucous membranes, or both. The swelling usually lasts a few hours to 72 hours and may appear as non-puritic, subcutaneous, or submucosal organ edema. It is characterized by localized swelling brought on by the release of histamine. Itching is rare, and usual areas of appearance include the hands, feet, face, and genitalia, with periorbital swelling being the most often. The main objective of this review article is to study in brief the classifications, etiology, pathophysiology, and clinical trial data by describing the recent advancement in the treatment of angioedema. Various research articles obtained from different journals indexed under Scopus and SCI were used to prepare the review article and for illustrative work software such as Biorender and Microsoft Word was used. Histamine-- mediated angioedema, linked to allergic reactions, coexists with urticaria. Bradykinin-mediated angioedema, exemplified by hereditary angioedema and acquired forms, lacks urticaria. Idiopathic angioedema, with uncertain etiology. Imitated angioedema results from non-IgE-mediated reactions, often induced by medications. It is a complicated medical condition with a variety of causes and mechanisms. Over time, outcomes for patients have been greatly improved by a growing understanding of its etiology, pathophysiology, and available treatments. The field of medical treatment for this difficult problem is always changing, and this is partly due to clinical trials.

血管性水肿是一种影响上肺和胃通路等身体部位的健康问题,表现为皮肤、粘膜或两者突然出现非点状肿大。肿胀通常持续几小时到 72 小时,可能表现为非瘙痒性、皮下或粘膜下器官水肿。其特点是组胺释放引起局部肿胀。瘙痒很少见,通常出现的部位包括手、脚、脸和生殖器,其中眶周肿胀最为常见。这篇综述文章的主要目的是简要研究血管性水肿的分类、病因学、病理生理学和临床试验数据,介绍治疗血管性水肿的最新进展。在撰写这篇综述文章时,使用了从 Scopus 和 SCI 收录的不同期刊上获取的各种研究文章,并使用了 Biorender 和 Microsoft Word 等软件进行说明工作。组胺介导的血管性水肿与荨麻疹并存,与过敏反应有关。缓激肽介导的血管性水肿,以遗传性血管性水肿和获得性血管性水肿为例,不伴有荨麻疹。特发性血管性水肿,病因不明。仿制性血管性水肿由非 IgE 介导的反应引起,通常由药物诱发。这是一种复杂的病症,病因和发病机制多种多样。随着时间的推移,人们对其病因、病理生理学和现有治疗方法的了解不断加深,患者的治疗效果也得到了极大改善。针对这一棘手问题的医疗领域一直在不断变化,这部分归功于临床试验。
{"title":"Etiology, Recent Advances, and Clinical Trials Data for the Treatment of Angioedema: A Review.","authors":"Mukul Nishad, Sushma Verma, Ramish Maqsood, Rashmi Saxena Pal","doi":"10.2174/0115748871307432240930051749","DOIUrl":"https://doi.org/10.2174/0115748871307432240930051749","url":null,"abstract":"<p><p>Angioedema is a health issue that affects parts of the body like the upper pulmonary and gastric pathways and is identified by abrupt, nonpitting enlargement of the skin, mucous membranes, or both. The swelling usually lasts a few hours to 72 hours and may appear as non-puritic, subcutaneous, or submucosal organ edema. It is characterized by localized swelling brought on by the release of histamine. Itching is rare, and usual areas of appearance include the hands, feet, face, and genitalia, with periorbital swelling being the most often. The main objective of this review article is to study in brief the classifications, etiology, pathophysiology, and clinical trial data by describing the recent advancement in the treatment of angioedema. Various research articles obtained from different journals indexed under Scopus and SCI were used to prepare the review article and for illustrative work software such as Biorender and Microsoft Word was used. Histamine-- mediated angioedema, linked to allergic reactions, coexists with urticaria. Bradykinin-mediated angioedema, exemplified by hereditary angioedema and acquired forms, lacks urticaria. Idiopathic angioedema, with uncertain etiology. Imitated angioedema results from non-IgE-mediated reactions, often induced by medications. It is a complicated medical condition with a variety of causes and mechanisms. Over time, outcomes for patients have been greatly improved by a growing understanding of its etiology, pathophysiology, and available treatments. The field of medical treatment for this difficult problem is always changing, and this is partly due to clinical trials.</p>","PeriodicalId":21174,"journal":{"name":"Reviews on recent clinical trials","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2024-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142473534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Navigating Dry Eye Research: A Comprehensive Review of Etiology, Clinical Trials, Patents, and Recent Advancements. 干眼症研究导航:全面回顾病因、临床试验、专利和最新进展。
IF 1.4 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-10-09 DOI: 10.2174/0115748871310261240929163138
Vindhya Pal, Sushma Verma

Background: Millions of people worldwide suffer from dry eye disease. Dry eye, a multifunctional condition of the ocular surface, typically occurs in conjunction with an unbalanced tear film. With increasing age, the dry eye problem becomes worse. Aqueous-deficit dry eye and evaporative dry eye are the two traditional classifications for dry eye. Various examination tools are used to diagnose dry eye. Clinical trials are conducted in four phases to check the safety and efficacy of drugs. The quick clearance from the precorneal space is ensured by the eye's advanced defense mechanism. It restricts the integrated medicine's entry into the eyes, resulting in a usually low bioavailability for topical eyedrops. In this study, we focus on recently developed formulations for curing dry eye.

Objective: This review's goal was to outline the etiology, clinical discovery and development, patents, and recent advancements for dry eye disease.

Results: The current study has described the widespread incidence of dry eye, which was found to be more common as people aged and recently developed formulations are treating dry eyes. According to research, novel formulations are enhancing ocular drug delivery.

Conclusion: In this review, etiology, clinical data, dry eye formulation patents, and recent advancements are all included.

背景:全世界有数百万人患有干眼症。干眼症是眼表的一种多功能疾病,通常与泪膜失衡同时发生。随着年龄的增长,干眼症会越来越严重。缺水性干眼症和蒸发性干眼症是干眼症的两种传统分类。诊断干眼症有多种检查工具。临床试验分四个阶段进行,以检查药物的安全性和有效性。眼球先进的防御机制确保了角膜前间隙的快速清除。它限制了综合药物进入眼睛,导致外用眼药水的生物利用度通常较低。在本研究中,我们将重点关注最近开发的用于治疗干眼症的配方:本综述旨在概述干眼症的病因、临床发现和发展、专利以及最新进展:目前的研究描述了干眼症的广泛发病率,发现随着年龄的增长,干眼症的发病率越来越高,最近开发的配方正在治疗干眼症。根据研究,新型配方正在加强眼部给药:本综述包括病因、临床数据、干眼症配方专利和最新进展。
{"title":"Navigating Dry Eye Research: A Comprehensive Review of Etiology, Clinical Trials, Patents, and Recent Advancements.","authors":"Vindhya Pal, Sushma Verma","doi":"10.2174/0115748871310261240929163138","DOIUrl":"https://doi.org/10.2174/0115748871310261240929163138","url":null,"abstract":"<p><strong>Background: </strong>Millions of people worldwide suffer from dry eye disease. Dry eye, a multifunctional condition of the ocular surface, typically occurs in conjunction with an unbalanced tear film. With increasing age, the dry eye problem becomes worse. Aqueous-deficit dry eye and evaporative dry eye are the two traditional classifications for dry eye. Various examination tools are used to diagnose dry eye. Clinical trials are conducted in four phases to check the safety and efficacy of drugs. The quick clearance from the precorneal space is ensured by the eye's advanced defense mechanism. It restricts the integrated medicine's entry into the eyes, resulting in a usually low bioavailability for topical eyedrops. In this study, we focus on recently developed formulations for curing dry eye.</p><p><strong>Objective: </strong>This review's goal was to outline the etiology, clinical discovery and development, patents, and recent advancements for dry eye disease.</p><p><strong>Results: </strong>The current study has described the widespread incidence of dry eye, which was found to be more common as people aged and recently developed formulations are treating dry eyes. According to research, novel formulations are enhancing ocular drug delivery.</p><p><strong>Conclusion: </strong>In this review, etiology, clinical data, dry eye formulation patents, and recent advancements are all included.</p>","PeriodicalId":21174,"journal":{"name":"Reviews on recent clinical trials","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142473535","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparison of the Effects of Dill Seed, Grape Seed and Date Extracts on Postpartum Hemorrhage Rates in the Fourth Stage of Labor: A Randomized Clinical Trial. 比较莳萝籽、葡萄籽和枣提取物对第四产程产后出血率的影响:随机临床试验。
IF 1.4 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-10-09 DOI: 10.2174/0115748871317272240930092220
Arezoo Shayan, Mansoureh Refaei, Hamideh Parsapour, Seyedeh Zahra Masoumi, Hassan Ahmadinia, Shirin Moradkhani, Mahtab Sattari, Minoo Hamoun

Background: Postpartum hemorrhage (PPH) is one of the three leading causes of maternal mortality. Herbal medicine is one of the well-known methods of treatment in the world.

Objective: This study was conducted to determine and compare the effect of dates, grape seed and dill seed extracts on the PPH rate in women in the fourth stage of labor.

Methods: Two hundred eligible multiparous women visiting the maternity ward in Hamadan for normal delivery participated in this double-blind parallel-group clinical trial. They were randomly divided into four 50-member groups of experiment (3 groups) and control (1 group). The data were collected using a researcher-made questionnaire. In the experimental groups, in addition to routine care and oxytocin administration, the mothers received a capsule containing 15 mg of dill seeds extract or 20 mg of grape seed extract or 5 g of dates extract immediately after the delivery, and then their hemorrhage rates were measured one and two hours after delivery. The control group received routine care, oxytocin, and placebo. Data were analyzed in SPSS 21.

Results: The hemorrhage changes in the placebo group were much less than the intervention groups at 1 and 2 hours after delivery, and the four groups had a significant difference in terms of hemorrhage in both hours (p <0.001). The overall difference between the dates extract group and the placebo and grape seed groups was also statistically significant (p <0.05).

Conclusion: All three extracts of dates, grape seed and dill seeds, especially dates, can be effective in PPH reduction.

Clinical trial registration number: IRCT20120215009014N300.

背景:产后出血(PPH)是导致产妇死亡的三大主要原因之一。草药是世界上众所周知的治疗方法之一:本研究旨在确定并比较红枣、葡萄籽和莳萝籽提取物对第四产程产妇 PPH 发生率的影响:200 名在哈马丹市产科病房顺产的合格多产妇参加了这项双盲平行组临床试验。她们被随机分为四组,每组 50 人,分别为实验组(3 组)和对照组(1 组)。数据通过研究人员制作的调查问卷收集。实验组的产妇除了接受常规护理和催产素注射外,还在产后立即服用含有 15 毫克莳萝籽提取物或 20 毫克葡萄籽提取物或 5 克红枣提取物的胶囊,然后在产后 1 小时和 2 小时测量出血率。对照组接受常规护理、催产素和安慰剂。数据用 SPSS 21 进行分析:结果:安慰剂组在产后 1 小时和 2 小时的出血量变化远小于干预组,四组在这两个小时的出血量有显著差异(P 结论:安慰剂组的出血量变化远小于干预组,四组在这两个小时的出血量有显著差异(P 结论:安慰剂组的出血量变化远小于干预组:红枣、葡萄籽、莳萝籽三种提取物,尤其是红枣提取物,均可有效降低PPH。
{"title":"Comparison of the Effects of Dill Seed, Grape Seed and Date Extracts on Postpartum Hemorrhage Rates in the Fourth Stage of Labor: A Randomized Clinical Trial.","authors":"Arezoo Shayan, Mansoureh Refaei, Hamideh Parsapour, Seyedeh Zahra Masoumi, Hassan Ahmadinia, Shirin Moradkhani, Mahtab Sattari, Minoo Hamoun","doi":"10.2174/0115748871317272240930092220","DOIUrl":"https://doi.org/10.2174/0115748871317272240930092220","url":null,"abstract":"<p><strong>Background: </strong>Postpartum hemorrhage (PPH) is one of the three leading causes of maternal mortality. Herbal medicine is one of the well-known methods of treatment in the world.</p><p><strong>Objective: </strong>This study was conducted to determine and compare the effect of dates, grape seed and dill seed extracts on the PPH rate in women in the fourth stage of labor.</p><p><strong>Methods: </strong>Two hundred eligible multiparous women visiting the maternity ward in Hamadan for normal delivery participated in this double-blind parallel-group clinical trial. They were randomly divided into four 50-member groups of experiment (3 groups) and control (1 group). The data were collected using a researcher-made questionnaire. In the experimental groups, in addition to routine care and oxytocin administration, the mothers received a capsule containing 15 mg of dill seeds extract or 20 mg of grape seed extract or 5 g of dates extract immediately after the delivery, and then their hemorrhage rates were measured one and two hours after delivery. The control group received routine care, oxytocin, and placebo. Data were analyzed in SPSS 21.</p><p><strong>Results: </strong>The hemorrhage changes in the placebo group were much less than the intervention groups at 1 and 2 hours after delivery, and the four groups had a significant difference in terms of hemorrhage in both hours (p <0.001). The overall difference between the dates extract group and the placebo and grape seed groups was also statistically significant (p <0.05).</p><p><strong>Conclusion: </strong>All three extracts of dates, grape seed and dill seeds, especially dates, can be effective in PPH reduction.</p><p><strong>Clinical trial registration number: </strong>IRCT20120215009014N300.</p>","PeriodicalId":21174,"journal":{"name":"Reviews on recent clinical trials","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142473533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Association between Gallstone Disease and Incidence of Cardiovascular Disease: A Systematic Review and Meta-Analysis. 胆石症与心血管疾病发病率之间的关系:系统回顾与元分析》。
IF 1.4 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-10-08 DOI: 10.2174/0115748871326450240926072451
Rasoul Rahimi, Saeid Heidari-Soureshjani, Catherine M T Sherwin, Karamali Kasiri, Ghorbanali Rahimian

Background: Gallstone Disease (GSD) is a multifactorial risk factor for various complications.

Objective: This study aimed to examine the relationship between GSD and Cardiovascular Disease (CVD) incidence through a systematic review and meta-analysis approach.

Methods: A thorough search was conducted across Web of Science, Scopus, MEDLINE/PubMed, Cochrane Library, and Embase databases. Only studies published between 1980 and December 2023 were included. Chi-square, I2, and forest plots were used to assess heterogeneity. Begg's and Egger's tests were used to evaluate publication bias. Statistical significance was considered at p <0.05, and all analyses were performed using Stata 17.

Results: This meta-analysis involved 21 studies and comprised 2,138,282 participants; there has been a significant association found between GSD and an increased risk of CVD (with a relative risk of 1.46, 95% confidence interval: 1.32-1.63, p <0.001). The analysis found no evidence of publication bias based on Begg's test (p =0.085) and Egger's test (p =0.231). Subgroup analysis of the studies showed a higher risk of CVD in studies with a sample size of less than 10,000 participants, conducted in 2016 or later, utilizing a cross-sectional design, in Asian countries; the analysis had a moderate quality score, with a follow-up period of equal to or less than ten years.

Conclusion: There has been a significant association found between GSD and an increased risk of incidence of CVD. Taking proactive steps to implement targeted interventions for individuals with gallstone disease could potentially reduce the risk of cardiovascular disease within this population.

背景:胆石症(GSD)是导致各种并发症的多因素风险因素:胆石症(GSD)是导致各种并发症的多因素风险因素:本研究旨在通过系统综述和荟萃分析方法研究 GSD 与心血管疾病(CVD)发病率之间的关系:在 Web of Science、Scopus、MEDLINE/PubMed、Cochrane Library 和 Embase 数据库中进行了全面检索。仅纳入 1980 年至 2023 年 12 月间发表的研究。采用Chi-square、I2和森林图评估异质性。Begg's 和 Egger's 检验用于评估发表偏倚。统计显著性以 p 为标准:这项荟萃分析涉及 21 项研究,共有 2 138 282 人参与;发现 GSD 与心血管疾病风险增加之间存在显著关联(相对风险为 1.46,95% 置信区间:1.32-1.63,p 结论:GSD 与心血管疾病风险增加之间存在显著关联:GSD 与心血管疾病发病风险增加之间存在明显关联。采取积极措施对胆石症患者进行有针对性的干预,有可能降低这一人群罹患心血管疾病的风险。
{"title":"The Association between Gallstone Disease and Incidence of Cardiovascular Disease: A Systematic Review and Meta-Analysis.","authors":"Rasoul Rahimi, Saeid Heidari-Soureshjani, Catherine M T Sherwin, Karamali Kasiri, Ghorbanali Rahimian","doi":"10.2174/0115748871326450240926072451","DOIUrl":"https://doi.org/10.2174/0115748871326450240926072451","url":null,"abstract":"<p><strong>Background: </strong>Gallstone Disease (GSD) is a multifactorial risk factor for various complications.</p><p><strong>Objective: </strong>This study aimed to examine the relationship between GSD and Cardiovascular Disease (CVD) incidence through a systematic review and meta-analysis approach.</p><p><strong>Methods: </strong>A thorough search was conducted across Web of Science, Scopus, MEDLINE/PubMed, Cochrane Library, and Embase databases. Only studies published between 1980 and December 2023 were included. Chi-square, I2, and forest plots were used to assess heterogeneity. Begg's and Egger's tests were used to evaluate publication bias. Statistical significance was considered at p <0.05, and all analyses were performed using Stata 17.</p><p><strong>Results: </strong>This meta-analysis involved 21 studies and comprised 2,138,282 participants; there has been a significant association found between GSD and an increased risk of CVD (with a relative risk of 1.46, 95% confidence interval: 1.32-1.63, p <0.001). The analysis found no evidence of publication bias based on Begg's test (p =0.085) and Egger's test (p =0.231). Subgroup analysis of the studies showed a higher risk of CVD in studies with a sample size of less than 10,000 participants, conducted in 2016 or later, utilizing a cross-sectional design, in Asian countries; the analysis had a moderate quality score, with a follow-up period of equal to or less than ten years.</p><p><strong>Conclusion: </strong>There has been a significant association found between GSD and an increased risk of incidence of CVD. Taking proactive steps to implement targeted interventions for individuals with gallstone disease could potentially reduce the risk of cardiovascular disease within this population.</p>","PeriodicalId":21174,"journal":{"name":"Reviews on recent clinical trials","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2024-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142392907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
From Patents to Progress: Unraveling Gout's Journey Through Clinical Trials and Advancements. 从专利到进步:通过临床试验和进展揭开痛风之谜。
IF 1.4 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-10-08 DOI: 10.2174/0115748871308473240926044126
Vikash Singh Bhadouria, Sushma Verma, Chhaya Agarwal, Deep Shikha Sharma

Gout, an inflammatory arthritis form, is renowned for its historical association with affluence. This review delves into its pathophysiology, exploring hyperuricemia, urate crystal formation, and the ensuing inflammatory response. The epidemiology of gout is examined, focusing on its rising prevalence and impact on public health. In this study, progress in gout management is discussed, involving pharmacological interventions, dietary changes, and emerging therapies. Genetic predisposition and triggers like alcohol, temperature, and diet are highlighted in this study. Prevention strategies, including serum urate-lowering therapy and lifestyle modifications, aim to reduce recurrent flares and complications. The inflammatory response in acute gout attacks is elucidated, involving immune cells, cytokines, and the NLRP3 inflammasome. Chronic gout manifestations, such as gouty tophus formation, are explored for their destructive impact on surrounding tissues. Recent advancements in gout treatment, including nanotherapies and novel compounds, are discussed, along with promising urate-lowering drugs. Cutting-edge research on zinc ferrite nanoparticles, dimethyl fumarate, and myricetin/nobiletin hybrids addresses oxidative stress and inflammation in gout. Additionally, the potential therapeutic role of methanolic leaf extract of Euphorbia milii and tip-loaded CLC-Soluplus® MAPs is explored as natural and transdermal alternatives for gout management. The review also covers the development status of new urate-lowering drugs, providing insights into promising candidates and their mechanisms. Patents on gout and recent diagnostic advancements using techniques like laser confocal micro Raman spectrometer, FTIR, and THz-TDS offer a more accurate approach for gout stone analysis, enabling early detection and targeted treatment.

痛风是一种炎症性关节炎,因其与富裕的历史渊源而闻名。这篇综述深入探讨了痛风的病理生理学,探讨了高尿酸血症、尿酸盐晶体的形成以及随之而来的炎症反应。研究还探讨了痛风的流行病学,重点关注其发病率的上升及其对公共卫生的影响。本研究讨论了痛风治疗的进展,包括药物干预、饮食改变和新兴疗法。本研究强调了遗传易感性以及酒精、温度和饮食等诱发因素。预防策略包括降低血清尿酸盐治疗和改变生活方式,旨在减少复发和并发症。研究阐明了痛风急性发作时的炎症反应,包括免疫细胞、细胞因子和NLRP3炎性体。研究还探讨了痛风的慢性表现,如痛风性脓肿的形成,以及它们对周围组织的破坏性影响。该书讨论了痛风治疗的最新进展,包括纳米疗法和新型化合物,以及前景看好的降尿酸药物。有关纳米铁氧体锌、富马酸二甲酯和三叶草素/龙葵素混合物的前沿研究探讨了痛风中的氧化应激和炎症问题。此外,还探讨了大戟科植物大戟的甲醇叶提取物和尖端装载的 CLC-Soluplus® MAPs 作为痛风治疗的天然透皮替代品的潜在治疗作用。该综述还涵盖了新的降尿酸药物的开发状况,对有前景的候选药物及其机制进行了深入探讨。有关痛风的专利以及最近利用激光共聚焦显微拉曼光谱仪、傅立叶变换红外光谱仪和太赫兹-TDS 等技术进行诊断的进展,为痛风石分析提供了更准确的方法,从而实现早期检测和有针对性的治疗。
{"title":"From Patents to Progress: Unraveling Gout's Journey Through Clinical Trials and Advancements.","authors":"Vikash Singh Bhadouria, Sushma Verma, Chhaya Agarwal, Deep Shikha Sharma","doi":"10.2174/0115748871308473240926044126","DOIUrl":"https://doi.org/10.2174/0115748871308473240926044126","url":null,"abstract":"<p><p>Gout, an inflammatory arthritis form, is renowned for its historical association with affluence. This review delves into its pathophysiology, exploring hyperuricemia, urate crystal formation, and the ensuing inflammatory response. The epidemiology of gout is examined, focusing on its rising prevalence and impact on public health. In this study, progress in gout management is discussed, involving pharmacological interventions, dietary changes, and emerging therapies. Genetic predisposition and triggers like alcohol, temperature, and diet are highlighted in this study. Prevention strategies, including serum urate-lowering therapy and lifestyle modifications, aim to reduce recurrent flares and complications. The inflammatory response in acute gout attacks is elucidated, involving immune cells, cytokines, and the NLRP3 inflammasome. Chronic gout manifestations, such as gouty tophus formation, are explored for their destructive impact on surrounding tissues. Recent advancements in gout treatment, including nanotherapies and novel compounds, are discussed, along with promising urate-lowering drugs. Cutting-edge research on zinc ferrite nanoparticles, dimethyl fumarate, and myricetin/nobiletin hybrids addresses oxidative stress and inflammation in gout. Additionally, the potential therapeutic role of methanolic leaf extract of Euphorbia milii and tip-loaded CLC-Soluplus® MAPs is explored as natural and transdermal alternatives for gout management. The review also covers the development status of new urate-lowering drugs, providing insights into promising candidates and their mechanisms. Patents on gout and recent diagnostic advancements using techniques like laser confocal micro Raman spectrometer, FTIR, and THz-TDS offer a more accurate approach for gout stone analysis, enabling early detection and targeted treatment.</p>","PeriodicalId":21174,"journal":{"name":"Reviews on recent clinical trials","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2024-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142392906","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Expression of Heat Shock Protein 90 in Testicular Cancer: A Retrospective Cohort Study. 睾丸癌中热休克蛋白 90 的表达:一项回顾性队列研究
IF 1.4 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-09-25 DOI: 10.2174/0115748871317252240919051309
Konstantinos Tzelepis, Ilias Giannakodimos, Vasileios Politis, Konstantinos Stamatiou, Ioannis Provatas, Evangelia Mitakidi, Vasileios Tzortzis, Sotirios Sotiriou

Background: The HSP90 marker is believed to play a constructive role in facilitating neoplastic transformation mainly via interaction with multiple pro-survival proteins. Welldesigned studies are needed to elucidate the role of HSP90 as a diagnostic marker and therapeutic target in testicular tumors.

Objective: The current study aimed to investigate the expression of HSP90 in various types of testicular cancer and highlight its expression in embryonal testicular cancer.

Material and methods: Immunohistochemical staining for HSP90 in 84 male patients, with nonmetastatic testicular cancer, who underwent orchiectomy from 2000 to 2023, was retrospectively performed at the Laboratory Department of General Hospital of Nikaia in Greece.

Results: A total of 84 males, with a mean age of 36.2 years, who have undergone high-cord radical orchiectomy, were included in this study. Out of the included males, 28.57% had embryonal carcinoma, 23.81% had seminoma, 19.05% had yolk sac tumor, 11.9% had mature teratoma, 9.52% had immature teratoma, and 7.14% had choriocarcinoma. HSP90b was positive in all embryonal carcinoma, seminoma, and choriocarcinoma cases, while it was positive in 75% of the yolk sac tumor, 75% of mature teratoma, and 75% of immature teratoma specimens. HSP90 was found negative in all choriocarcinoma, mature teratoma, and immature teratoma specimens, while it was positive in 25% of yolk sac tumor, 8.33% of embryonal carcinoma, and 10% of seminoma cases. Concerning the expression of HSP90b, a statistically significant relationship was found between excised tumor specimens and normal parenchyma specimens, especially in sac cases (p <0.001). Regarding HSP90a expression, a statistically significant relationship (OR=21.5, p =0.021) was found between excised tumor specimens and normal parenchyma specimens, especially in embryonal carcinoma cases (p <0.001).

Conclusion: HSP90b is highly expressed in the majority of the types of testicular tumors, both in tumor and normal parenchyma specimens, while HSP90a staining is negative in resected specimens. Further well-designed studies are needed to elucidate the role of HSP90 as a diagnostic marker and therapeutic target in testicular tumors.

背景:据信,HSP90标记物主要通过与多种促生存蛋白相互作用,在促进肿瘤转化方面发挥建设性作用。要阐明 HSP90 在睾丸肿瘤中作为诊断标记物和治疗靶点的作用,需要进行精心设计的研究:本研究旨在调查 HSP90 在各种类型睾丸癌中的表达,并强调其在胚胎性睾丸癌中的表达:希腊尼卡亚综合医院检验科对2000年至2023年期间接受睾丸切除术的84名非转移性睾丸癌男性患者进行了HSP90免疫组化染色:本研究共纳入 84 名接受过高脐根治性睾丸切除术的男性,他们的平均年龄为 36.2 岁。在这些男性患者中,28.57%患有胚胎癌,23.81%患有精索瘤,19.05%患有卵黄囊肿瘤,11.9%患有成熟畸胎瘤,9.52%患有未成熟畸胎瘤,7.14%患有绒毛膜癌。HSP90b在所有胚胎癌、精原细胞瘤和绒毛膜癌病例中均呈阳性,而在75%的卵黄囊肿瘤、75%的成熟畸胎瘤和75%的未成熟畸胎瘤标本中均呈阳性。HSP90在所有绒毛膜癌、成熟畸胎瘤和未成熟畸胎瘤标本中均为阴性,而在25%的卵黄囊肿瘤、8.33%的胚胎癌和10%的精原细胞瘤中呈阳性。关于 HSP90b 的表达,切除的肿瘤标本与正常实质标本之间存在统计学意义上的显著关系,尤其是在卵黄囊病例中(p 结论:HSP90b 在卵黄囊肿瘤中高表达:在大多数类型的睾丸肿瘤中,HSP90b在肿瘤和正常实质标本中均高表达,而在切除标本中HSP90a染色为阴性。要阐明 HSP90 在睾丸肿瘤中作为诊断标记物和治疗靶点的作用,还需要进一步开展精心设计的研究。
{"title":"Expression of Heat Shock Protein 90 in Testicular Cancer: A Retrospective Cohort Study.","authors":"Konstantinos Tzelepis, Ilias Giannakodimos, Vasileios Politis, Konstantinos Stamatiou, Ioannis Provatas, Evangelia Mitakidi, Vasileios Tzortzis, Sotirios Sotiriou","doi":"10.2174/0115748871317252240919051309","DOIUrl":"https://doi.org/10.2174/0115748871317252240919051309","url":null,"abstract":"<p><strong>Background: </strong>The HSP90 marker is believed to play a constructive role in facilitating neoplastic transformation mainly via interaction with multiple pro-survival proteins. Welldesigned studies are needed to elucidate the role of HSP90 as a diagnostic marker and therapeutic target in testicular tumors.</p><p><strong>Objective: </strong>The current study aimed to investigate the expression of HSP90 in various types of testicular cancer and highlight its expression in embryonal testicular cancer.</p><p><strong>Material and methods: </strong>Immunohistochemical staining for HSP90 in 84 male patients, with nonmetastatic testicular cancer, who underwent orchiectomy from 2000 to 2023, was retrospectively performed at the Laboratory Department of General Hospital of Nikaia in Greece.</p><p><strong>Results: </strong>A total of 84 males, with a mean age of 36.2 years, who have undergone high-cord radical orchiectomy, were included in this study. Out of the included males, 28.57% had embryonal carcinoma, 23.81% had seminoma, 19.05% had yolk sac tumor, 11.9% had mature teratoma, 9.52% had immature teratoma, and 7.14% had choriocarcinoma. HSP90b was positive in all embryonal carcinoma, seminoma, and choriocarcinoma cases, while it was positive in 75% of the yolk sac tumor, 75% of mature teratoma, and 75% of immature teratoma specimens. HSP90 was found negative in all choriocarcinoma, mature teratoma, and immature teratoma specimens, while it was positive in 25% of yolk sac tumor, 8.33% of embryonal carcinoma, and 10% of seminoma cases. Concerning the expression of HSP90b, a statistically significant relationship was found between excised tumor specimens and normal parenchyma specimens, especially in sac cases (p <0.001). Regarding HSP90a expression, a statistically significant relationship (OR=21.5, p =0.021) was found between excised tumor specimens and normal parenchyma specimens, especially in embryonal carcinoma cases (p <0.001).</p><p><strong>Conclusion: </strong>HSP90b is highly expressed in the majority of the types of testicular tumors, both in tumor and normal parenchyma specimens, while HSP90a staining is negative in resected specimens. Further well-designed studies are needed to elucidate the role of HSP90 as a diagnostic marker and therapeutic target in testicular tumors.</p>","PeriodicalId":21174,"journal":{"name":"Reviews on recent clinical trials","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2024-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142352949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Review of Association Between Urinary Tract Infections and Immunosuppressive Drugs after Heart Transplantation. 回顾心脏移植术后尿路感染与免疫抑制药物之间的关系
IF 1.4 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-09-25 DOI: 10.2174/0115748871315445240916091528
Zahra Tolou-Ghamari

Management of infections in heart transplant recipients is complex and crucial. In this population, there is a need for a better understanding of immunosuppressive trough levels (C0), infectious complications, and urinary tract infections (UTIs). The purpose of this review was to understand the association between immunosuppressive trough levels and UTIs after heart transplantation. A review of scientific literature (n= 100) was conducted based on the topic of interest by searching PUBMED.Gov (https://pubmed.ncbi.nlm.nih.gov/), Web of Science, and Scopus. The analysis of bacterial pulmonary infection required the occurrence of new or deteriorating pulmonary infiltrates and the development of organisms in cultures of sputum specimens. The diagnosis of UTIs was based on the result of related signs, pyuria, and a positive urine culture. The incidence of UTIs was reported as 0.07 episodes/1000 regarding heart transplantation days. An eightfold increase in the rate of rejection was noted in heart transplant recipients with higher variability in tacrolimus C0. There are associations between C0 of immunosuppressive drugs and clinical presentation of infection complications. Recipients with a low metabolism of immunosuppressive drugs are more susceptible to infectious complications. Attention to the biology of herpes viruses, Escherichia coli, Enterococcus spp., Pseudomonas aeruginosa, and Staphylococcus saprophyticus after heart transplantation are important, in which some of them are the most common pathogens responsible for UTIs. Pneumocystis and cytomegalovirus affect all transplant recipients. Pneumonia due to bacterial, viral, protozoa, and fungal infections, in addition to UTIs, are more specific reported types of infections in heart transplant recipients. Bacterial infections produced by extensively drug-resistant Enterobacteriaceae, vancomycin-resistant enterococci, and non-fermenting gramnegative bacteria were reported to increase after transplantation.

心脏移植受者的感染管理既复杂又关键。在这一人群中,需要更好地了解免疫抑制剂谷值水平(C0)、感染并发症和尿路感染(UTI)。本综述旨在了解心脏移植后免疫抑制剂谷值水平与UTIs之间的关系。根据感兴趣的主题,通过搜索 PUBMED.Gov (https://pubmed.ncbi.nlm.nih.gov/)、Web of Science 和 Scopus,对科学文献(n= 100)进行了综述。对肺部细菌感染的分析要求出现新的或恶化的肺部浸润,以及痰标本培养中出现微生物。尿路感染的诊断依据是相关体征、脓尿和尿培养阳性的结果。据报道,在心脏移植日中,尿毒症的发病率为 0.07 次/1000 天。在他克莫司 C0 变异性较高的心脏移植受者中,排斥反应的发生率增加了八倍。免疫抑制剂的 C0 与感染并发症的临床表现之间存在关联。免疫抑制剂代谢率低的受者更容易出现感染并发症。在心脏移植后,关注疱疹病毒、大肠杆菌、肠球菌属、绿脓杆菌和溶血性葡萄球菌的生物学特性非常重要,其中一些是导致UTIs的最常见病原体。肺囊虫和巨细胞病毒会影响所有移植受者。除尿毒症外,细菌、病毒、原生动物和真菌感染导致的肺炎是心脏移植受者感染的更特殊类型。据报道,由广泛耐药肠杆菌科细菌、耐万古霉素肠球菌和不发酵革兰氏阴性菌引起的细菌感染在移植后有所增加。
{"title":"Review of Association Between Urinary Tract Infections and Immunosuppressive Drugs after Heart Transplantation.","authors":"Zahra Tolou-Ghamari","doi":"10.2174/0115748871315445240916091528","DOIUrl":"https://doi.org/10.2174/0115748871315445240916091528","url":null,"abstract":"<p><p>Management of infections in heart transplant recipients is complex and crucial. In this population, there is a need for a better understanding of immunosuppressive trough levels (C0), infectious complications, and urinary tract infections (UTIs). The purpose of this review was to understand the association between immunosuppressive trough levels and UTIs after heart transplantation. A review of scientific literature (n= 100) was conducted based on the topic of interest by searching PUBMED.Gov (https://pubmed.ncbi.nlm.nih.gov/), Web of Science, and Scopus. The analysis of bacterial pulmonary infection required the occurrence of new or deteriorating pulmonary infiltrates and the development of organisms in cultures of sputum specimens. The diagnosis of UTIs was based on the result of related signs, pyuria, and a positive urine culture. The incidence of UTIs was reported as 0.07 episodes/1000 regarding heart transplantation days. An eightfold increase in the rate of rejection was noted in heart transplant recipients with higher variability in tacrolimus C0. There are associations between C0 of immunosuppressive drugs and clinical presentation of infection complications. Recipients with a low metabolism of immunosuppressive drugs are more susceptible to infectious complications. Attention to the biology of herpes viruses, Escherichia coli, Enterococcus spp., Pseudomonas aeruginosa, and Staphylococcus saprophyticus after heart transplantation are important, in which some of them are the most common pathogens responsible for UTIs. Pneumocystis and cytomegalovirus affect all transplant recipients. Pneumonia due to bacterial, viral, protozoa, and fungal infections, in addition to UTIs, are more specific reported types of infections in heart transplant recipients. Bacterial infections produced by extensively drug-resistant Enterobacteriaceae, vancomycin-resistant enterococci, and non-fermenting gramnegative bacteria were reported to increase after transplantation.</p>","PeriodicalId":21174,"journal":{"name":"Reviews on recent clinical trials","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2024-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142352950","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of Colchicine for Prevention of Recurrent Stroke in Ischemic Stroke Patients with Atrial Fibrillation: A Randomized Double-blinded Placebo-- controlled Trial. 心房颤动缺血性卒中患者服用秋水仙碱预防复发性卒中的效果:随机双盲安慰剂对照试验》。
IF 1.4 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-09-19 DOI: 10.2174/0115748871325292240904060109
Zahra Molaeimanesh, Davood Kashipazha, Davood Shalilahmadi, Gholamreza Shamsaei, Shooka Mohammadi

Background: It has been proposed that colchicine may have the potential to prevent cardiovascular and cerebrovascular dysfunctions.

Objective: This study evaluated the impact of colchicine on preventing recurrent stroke in patients with both ischemic stroke (IS) and atrial fibrillation (AF).

Methods: A randomized, double-blinded, placebo-controlled trial was conducted at Golestan Hospital (Ahvaz, Iran) over one year, involving IS patients with AF. Demographic and clinical data were collected from the participants, who were then assigned to either the intervention or placebo groups. The experimental group was administered colchicine at a dosage of 0.05 mg twice daily for one year, while the control group received a placebo at a comparable dosage over the same timeframe.

Results: In one year, 108 patients completed the study. There were 55 patients in the intervention group and 53 patients in the placebo group. During the second trimester of the trial, three patients in the colchicine group and 10 patients in the placebo group experienced recurrent strokes. Gastrointestinal issues were the most commonly reported complications (33 cases), followed by myalgia (8 patients). There were significant differences in the frequency of recurrent stroke and serum levels of C-reactive protein (CRP) between the colchicine and placebo groups (P < 0.05) after intervention.

Conclusion: In this study, colchicine was effective in reducing recurrent stroke and CRP levels in IS patients with AF compared to the control group. Further randomized controlled trials with larger sample sizes and extended durations are recommended to validate the results of this trial.

背景:有人认为秋水仙碱可能具有预防心脑血管功能障碍的潜力:有人认为秋水仙碱可能具有预防心脑血管功能障碍的潜力:本研究评估了秋水仙碱对预防缺血性中风(IS)和心房颤动(AF)患者复发中风的影响:方法: 在戈勒斯坦医院(伊朗阿瓦士)进行了一项为期一年的随机、双盲、安慰剂对照试验,研究对象为缺血性中风(IS)合并心房颤动患者。试验收集了参与者的人口统计学和临床数据,然后将他们分配到干预组或安慰剂组。实验组服用秋水仙碱,剂量为 0.05 毫克,每天两次,为期一年;对照组在相同时间内服用剂量相当的安慰剂:一年中,108 名患者完成了研究。干预组有 55 名患者,安慰剂组有 53 名患者。在试验的后三个月中,秋水仙碱组有 3 名患者、安慰剂组有 10 名患者出现中风复发。胃肠道问题是最常见的并发症(33 例),其次是肌痛(8 例)。干预后,秋水仙碱组和安慰剂组的中风复发频率和血清 C 反应蛋白(CRP)水平存在明显差异(P < 0.05):结论:在本研究中,与对照组相比,秋水仙碱能有效降低房颤 IS 患者的卒中复发率和 CRP 水平。建议进一步开展样本量更大、持续时间更长的随机对照试验,以验证本试验的结果。
{"title":"Effect of Colchicine for Prevention of Recurrent Stroke in Ischemic Stroke Patients with Atrial Fibrillation: A Randomized Double-blinded Placebo-- controlled Trial.","authors":"Zahra Molaeimanesh, Davood Kashipazha, Davood Shalilahmadi, Gholamreza Shamsaei, Shooka Mohammadi","doi":"10.2174/0115748871325292240904060109","DOIUrl":"https://doi.org/10.2174/0115748871325292240904060109","url":null,"abstract":"<p><strong>Background: </strong>It has been proposed that colchicine may have the potential to prevent cardiovascular and cerebrovascular dysfunctions.</p><p><strong>Objective: </strong>This study evaluated the impact of colchicine on preventing recurrent stroke in patients with both ischemic stroke (IS) and atrial fibrillation (AF).</p><p><strong>Methods: </strong>A randomized, double-blinded, placebo-controlled trial was conducted at Golestan Hospital (Ahvaz, Iran) over one year, involving IS patients with AF. Demographic and clinical data were collected from the participants, who were then assigned to either the intervention or placebo groups. The experimental group was administered colchicine at a dosage of 0.05 mg twice daily for one year, while the control group received a placebo at a comparable dosage over the same timeframe.</p><p><strong>Results: </strong>In one year, 108 patients completed the study. There were 55 patients in the intervention group and 53 patients in the placebo group. During the second trimester of the trial, three patients in the colchicine group and 10 patients in the placebo group experienced recurrent strokes. Gastrointestinal issues were the most commonly reported complications (33 cases), followed by myalgia (8 patients). There were significant differences in the frequency of recurrent stroke and serum levels of C-reactive protein (CRP) between the colchicine and placebo groups (P < 0.05) after intervention.</p><p><strong>Conclusion: </strong>In this study, colchicine was effective in reducing recurrent stroke and CRP levels in IS patients with AF compared to the control group. Further randomized controlled trials with larger sample sizes and extended durations are recommended to validate the results of this trial.</p>","PeriodicalId":21174,"journal":{"name":"Reviews on recent clinical trials","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2024-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142294203","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Reviews on recent clinical trials
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1